QL9-21
QL9-21 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Mar 18, 2026: “LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates”.
1 paper studies it2 findingsUpdated
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- 2 of 2 findings with company ties
- Animals1
What did studies of QL9-21 find?
2Studies of QL9-21 measured 2 outcomes: liver accumulation and viral genome delivery to brain.
Liver accumulation
downin non-human primates1
1 study
Liver accumulation
downin non-human primates1
QL9-21 decreases liver accumulation in non-human primates (2.6 fold reduction).
“while concurrently reducing liver accumulation by 2.6 fold”
Animalsliver
bioRxivPreprint
Viral genome delivery to brain
upin non-human primates1
1 study
Viral genome delivery to brain
upin non-human primates1
QL9-21 increases viral genome delivery to brain in non-human primates (3-40 fold enhancement).
“mediated a striking 3-40 fold enhancement in viral genome delivery across all examined brain regions versus AAV9”
Animalsbrain
bioRxivPreprint